BioSpace News Archive

As usual, it was a busy week for clinical trial updates. Here’s a look.

The company has doubled its headcount to about 60 employees and doubled its square-footage in the city with the 26,000 square-foot facility.

The approval marks the first time a Korean company independently brought a drug from discovery to FDA approval.

A consortium jointly led by Astorg and Cinven announces that it has signed an agreement to acquire LGC, a global leader in the Life Sciences Tools sector.

Researchers have tested a new drug combination that shows promise for the treatment of several types of childhood brain cancers known as diffuse midline gliomas.

Akers Biosciences, Inc. (NASDAQ: AKER), (“Akers Bio” or the “Company”), a developer of rapid health information technologies, today announced that effective at 8:00 a.m. eastern standard time on Monday, November 25, 2019, the Company will effect a reverse stock split of its issued and outstanding common stock of no par value at a ratio of one (1) share of common stock for every twenty four (24) shares of common stock

Celularity, Inc. (“Celularity” ), a clinical-stage cell therapeutics company focused on the development of innovative allogeneic cellular therapies from human placentas, today announced pre-clinical data supporting the advancement of CYNK-001, a placental-derived, cryopreserved natural killer (NK) cell therapy, as a clinical candidate for patients with glioblastoma multiforme (GBM) in a poster presentation at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting in Phoenix, A.Z.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will today present positive results from the Phase III IMbrave150 study evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab)

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the presentation of real-world data for the treatment of patients with carotid artery disease at risk for stroke at the VEITHsymposium.

Versant Health, a leading national managed eye health and vision plan company, is proud to announce that their Senior Vice President of Medical Management—Elizabeth Klunk, RN, BSN, CCM-R—was a Silver Stevie® winner for Female Executive of the Year (Business Products) at the 16th annual Stevie Awards for Women in Business on Friday, November 15, 2019.